Eagle Pharmaceuticals Reports First Quarter 2021 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to  Eagle Pharmaceuticals Reports First Quarter 2021 Results

Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 21c, Revenues Miss

May 10, 2021 6:55 AM EDT

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $0.86, $0.21 better than the analyst estimate of $0.65. Revenue for the quarter came in at $41.2 million versus the consensus estimate of $45.41 million.

First Quarter 2021

Total revenue for Q1 2021 was $41.2 million, compared to $46.0 million in Q1 2020, primarily reflecting decreased product sales of RYANODEX® and royalty revenue of BENDEKA®.

Q1 2021 net loss was $0.4 million, or $0.03 per basic and... More